-
1
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
2
-
-
33947246190
-
Predictors of early recurrence in postmenopausal women with operable breast cancer
-
Abstract 2091.
-
Mansell J., Monypenny I., Skene A., et al. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res Treat 100 Suppl 1 (2006) S111 Abstract 2091.
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Mansell, J.1
Monypenny, I.2
Skene, A.3
-
3
-
-
14644413523
-
The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma
-
Monteiro Grillo I., Jorge M., Marques Vidal P., Ortiz M., and Ravasco P. The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma. Clin Oncol (R Coll Radiol) 17 (2005) 111-117
-
(2005)
Clin Oncol (R Coll Radiol)
, vol.17
, pp. 111-117
-
-
Monteiro Grillo, I.1
Jorge, M.2
Marques Vidal, P.3
Ortiz, M.4
Ravasco, P.5
-
4
-
-
33646758467
-
Breast cancer recurrence and related mortality in US pts with early breast cancer
-
Abstract 738.
-
Lamerato L., Havstad S., Gandhi S., Jones D., and Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 23 16S (2005) 62S Abstract 738.
-
(2005)
J Clin Oncol
, vol.23
, Issue.16 S
-
-
Lamerato, L.1
Havstad, S.2
Gandhi, S.3
Jones, D.4
Chlebowski, R.5
-
5
-
-
0037157603
-
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of theATAC randomised trial
-
ATAC Trialists' Group
-
Baum M., Budzar A., Cuzick J., et al., ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of theATAC randomised trial. Lancet 359 (2002) 2131-2139
-
(2002)
Lancet
, vol.359
, pp. 2131-2139
-
-
Baum, M.1
Budzar, A.2
Cuzick, J.3
-
6
-
-
0142181118
-
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
-
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group
-
Baum M., Buzdar A., Cuzick J., et al., The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
-
(2003)
Cancer
, vol.98
, pp. 1802-1810
-
-
Baum, M.1
Buzdar, A.2
Cuzick, J.3
-
7
-
-
11444251764
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
ATAC Trialists' Group
-
Howell A., Cuzick J., Baum M., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
-
(2005)
Lancet
, vol.365
, pp. 60-62
-
-
Howell, A.1
Cuzick, J.2
Baum, M.3
-
8
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
for the Breast International Group (BIG) 1-98 Collaborative Group
-
Thürlimann B., Keshaviah A., Coates A., et al., for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
-
(2005)
N Engl J Med
, vol.353
, pp. 2747-2757
-
-
Thürlimann, B.1
Keshaviah, A.2
Coates, A.3
-
9
-
-
33947510501
-
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
-
Coates A., Keshaviah A., Thürlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
-
(2007)
J Clin Oncol
, vol.25
, pp. 486-492
-
-
Coates, A.1
Keshaviah, A.2
Thürlimann, B.3
-
10
-
-
33645950746
-
Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials
-
Jones S. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials. Clin Breast Cancer 6 Suppl 2 (2006) S41-S44
-
(2006)
Clin Breast Cancer
, vol.6
, Issue.SUPPL. 2
-
-
Jones, S.1
-
11
-
-
10744223655
-
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
-
Coombes R., Hall E., Gibson L., et al., Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
-
(2004)
N Engl J Med
, vol.350
, pp. 1081-1092
-
-
Coombes, R.1
Hall, E.2
Gibson, L.3
-
12
-
-
33751321384
-
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early- stage breast cancer: a meta-analysis
-
Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early- stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
-
(2006)
Lancet Oncol
, vol.7
, pp. 991-996
-
-
Jonat, W.1
Gnant, M.2
Boccardo, F.3
-
13
-
-
7444259675
-
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
-
Goss P., Ingle J., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
-
(2003)
N Engl J Med
, vol.349
, pp. 1793-1802
-
-
Goss, P.1
Ingle, J.2
Martino, S.3
-
14
-
-
24744450378
-
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
-
Goss P., Ingle J., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 1262-1271
-
-
Goss, P.1
Ingle, J.2
Martino, S.3
-
15
-
-
34247864457
-
Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33
-
Abstract 49.
-
Mamounas E., Jeong J.-H., Wickerham L., et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100 Suppl 1 (2006) S22 Abstract 49.
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Mamounas, E.1
Jeong, J.-H.2
Wickerham, L.3
-
16
-
-
23444435619
-
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
-
Abstract 526.
-
Jakesz R., Samonigg H., Greil R., et al., on behalf of the ABCSG. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23 16 Suppl (2005) 10S Abstract 526.
-
(2005)
J Clin Oncol
, vol.23
, Issue.16 SUPPL
-
-
Jakesz, R.1
Samonigg, H.2
Greil, R.3
-
17
-
-
33846545851
-
Survival and safety of exemestane versus tamoxifen after 2 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
-
Coombes R., Kilburn L., Snowdon C., et al., Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
-
(2007)
Lancet
, vol.369
, pp. 559-570
-
-
Coombes, R.1
Kilburn, L.2
Snowdon, C.3
-
18
-
-
33751241251
-
-
AstraZeneca Pharmaceuticals LP, Wilmington, DE
-
Arimidex package insert (2005), AstraZeneca Pharmaceuticals LP, Wilmington, DE
-
(2005)
Arimidex package insert
-
-
-
19
-
-
34948831626
-
Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) data reported on behalf of the ATAC ("Arimidex", tamoxifen, alone or in Combination) Trialists' group
-
Abstract 243PD.
-
Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) data reported on behalf of the ATAC ("Arimidex", tamoxifen, alone or in Combination) Trialists' group. Ann Oncol 17 Suppl 9 (2006) ix94 Abstract 243PD.
-
(2006)
Ann Oncol
, vol.17
, Issue.SUPPL. 9
-
-
Houghton, J.1
-
20
-
-
34249292099
-
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
-
Mauriac L., Keshaviah A., Debled M., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18 (2007) 859-867
-
(2007)
Ann Oncol
, vol.18
, pp. 859-867
-
-
Mauriac, L.1
Keshaviah, A.2
Debled, M.3
-
21
-
-
35548937114
-
Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC)
-
Abstract 2084.
-
Vakaet L., and Buyse M. Comparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC). Breast Cancer Res Treat 100 Suppl 1 (2006) S108-S109 Abstract 2084.
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Vakaet, L.1
Buyse, M.2
-
22
-
-
38949204962
-
-
Rugo HS, Kaura S, Dranitsaris G. The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in post menopausal women with early breast cancer. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 170.
-
Rugo HS, Kaura S, Dranitsaris G. The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in post menopausal women with early breast cancer. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 170.
-
-
-
-
23
-
-
33845283976
-
The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8
-
Abstract 13.
-
Jakesz R., Gnant M., Greil R., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 94 Suppl 1 (2005) S10 Abstract 13.
-
(2005)
Breast Cancer Res Treat
, vol.94
, Issue.SUPPL. 1
-
-
Jakesz, R.1
Gnant, M.2
Greil, R.3
-
25
-
-
35548998081
-
Letrozole is more cost- effective than tamoxifen as early adjuvant therapy in multiple sub-groups of postmenopausal women with early breast cancer: the UK perspective
-
Abstract 5052.
-
Karnon J., Kaura S., and di Trapani F. Letrozole is more cost- effective than tamoxifen as early adjuvant therapy in multiple sub-groups of postmenopausal women with early breast cancer: the UK perspective. Breast Cancer Res Treat 100 Suppl 1 (2006) S230 Abstract 5052.
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Karnon, J.1
Kaura, S.2
di Trapani, F.3
-
26
-
-
38949133121
-
-
Karnon J, di Tripani F, Kaura S. Comparison of the cost per distant disease-free year gained of upfront letrozole or anastrozole, or switched exemestane vs tamoxifen for early breast cancer in hormone- receptor positive a(HR+) postmenopausal women: the UK perspective. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 179.
-
Karnon J, di Tripani F, Kaura S. Comparison of the cost per distant disease-free year gained of upfront letrozole or anastrozole, or switched exemestane vs tamoxifen for early breast cancer in hormone- receptor positive a(HR+) postmenopausal women: the UK perspective. Presented at the 10th International Conference: Primary Therapy of Early Breast Cancer; March 14 17, 2007; St. Gallen, Switzerland. Abstract 179.
-
-
-
-
27
-
-
2442684453
-
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion- negative early breast cancers without adjuvant systemic therapies
-
Chia S., Speers C., Bryce C., Hayes M., and Olivotto I. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion- negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 (2004) 1630-1637
-
(2004)
J Clin Oncol
, vol.22
, pp. 1630-1637
-
-
Chia, S.1
Speers, C.2
Bryce, C.3
Hayes, M.4
Olivotto, I.5
-
28
-
-
33846550085
-
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
-
Kennecke H., Olivotto I., Speers C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18 (2007) 45-51
-
(2007)
Ann Oncol
, vol.18
, pp. 45-51
-
-
Kennecke, H.1
Olivotto, I.2
Speers, C.3
-
30
-
-
38949159753
-
-
Peto R, Davies C; on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13 16, 2007; San Antonio, Texas. Abstract 48.
-
Peto R, Davies C; on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13 16, 2007; San Antonio, Texas. Abstract 48.
-
-
-
-
31
-
-
0035795683
-
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
-
Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 (2001) 684-690
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 684-690
-
-
Fisher, B.1
Dignam, J.2
Bryant, J.3
Wolmark, N.4
-
32
-
-
38949161221
-
-
Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2007 May 3 [Epub ahead of print].
-
Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2007 May 3 [Epub ahead of print].
-
-
-
-
33
-
-
33749078918
-
Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding
-
Abstract 550.
-
Robert N., Goss P., Ingle J., et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. J Clin Oncol 24 18S (2006) 15s Abstract 550.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 S
-
-
Robert, N.1
Goss, P.2
Ingle, J.3
-
34
-
-
0035038371
-
Neoadjuvant therapy in breast cancer: can we define its role?
-
Aapro M. Neoadjuvant therapy in breast cancer: can we define its role?. Oncologist 6 (2001) 36-39
-
(2001)
Oncologist
, vol.6
, pp. 36-39
-
-
Aapro, M.1
-
35
-
-
24644490871
-
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
-
IMPACT Trialists Group
-
Smith I., Dowsett M., Ebbs S., et al., IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 (2005) 5108-5116
-
(2005)
J Clin Oncol
, vol.23
, pp. 5108-5116
-
-
Smith, I.1
Dowsett, M.2
Ebbs, S.3
-
36
-
-
33646371731
-
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial
-
Cataliotti L., Buzdar A., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106 (2006) 2095-2103
-
(2006)
Cancer
, vol.106
, pp. 2095-2103
-
-
Cataliotti, L.1
Buzdar, A.2
Noguchi, S.3
-
37
-
-
0035692576
-
Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study
-
Letrozole Neo-Adjuvant Breast Cancer Study Group
-
Eiermann W., Paepke S., Appfelstaedt J., et al., Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
-
(2001)
Ann Oncol
, vol.12
, pp. 1527-1532
-
-
Eiermann, W.1
Paepke, S.2
Appfelstaedt, J.3
-
38
-
-
0032974458
-
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast
-
Miller W. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 6 (1999) 187-195
-
(1999)
Endocr Relat Cancer
, vol.6
, pp. 187-195
-
-
Miller, W.1
-
39
-
-
0034982329
-
Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors
-
Bhatnagar A., Brodie A., Long B., Evans D., and Miller W. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76 (2001) 199-202
-
(2001)
J Steroid Biochem Mol Biol
, vol.76
, pp. 199-202
-
-
Bhatnagar, A.1
Brodie, A.2
Long, B.3
Evans, D.4
Miller, W.5
-
40
-
-
22744437908
-
Letrozole in the treatment of breast cancer
-
Mouridsen H., and Bhatnagar A. Letrozole in the treatment of breast cancer. Expert Opin Pharmacother 6 (2005) 1389-1399
-
(2005)
Expert Opin Pharmacother
, vol.6
, pp. 1389-1399
-
-
Mouridsen, H.1
Bhatnagar, A.2
-
41
-
-
0027167698
-
Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds
-
Furet P., Batzl C., Bhatnagar A., Francotte E., Rihs G., and Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem 36 (1993) 1393-1400
-
(1993)
J Med Chem
, vol.36
, pp. 1393-1400
-
-
Furet, P.1
Batzl, C.2
Bhatnagar, A.3
Francotte, E.4
Rihs, G.5
Lang, M.6
-
42
-
-
0036467847
-
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
-
Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
-
(2002)
J Clin Oncol
, vol.20
, pp. 751-757
-
-
Geisler, J.1
Haynes, B.2
Anker, G.3
Dowsett, M.4
Lonning, P.5
-
43
-
-
34249321005
-
Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole
-
Abstract 103.
-
Geisler J. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res Treat 100 Suppl 1 (2006) S23-S24 Abstract 103.
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
Geisler, J.1
-
44
-
-
33749505914
-
Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer
-
Abstract 552.
-
Dixon J., Renshaw L., Young O., et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 24 18S (2006) 15S Abstract 552.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 S
-
-
Dixon, J.1
Renshaw, L.2
Young, O.3
-
45
-
-
0031123311
-
Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate
-
Lonning P., Geisler J., Johannessen D., et al. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J Steroid Biochem Mol Biol 61 (1997) 255-260
-
(1997)
J Steroid Biochem Mol Biol
, vol.61
, pp. 255-260
-
-
Lonning, P.1
Geisler, J.2
Johannessen, D.3
-
46
-
-
7344242595
-
Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)
-
Gershanovich M., Chaudri H., Campos D., et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 9 (1998) 639-645
-
(1998)
Ann Oncol
, vol.9
, pp. 639-645
-
-
Gershanovich, M.1
Chaudri, H.2
Campos, D.3
-
48
-
-
33947255652
-
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
-
Jonat W., and Mundhenke C. The FACE trial: letrozole or anastrozole as initial adjuvant therapy?. Cancer Invest 25 (2007) 14-18
-
(2007)
Cancer Invest
, vol.25
, pp. 14-18
-
-
Jonat, W.1
Mundhenke, C.2
-
49
-
-
33750687260
-
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial
-
Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev Anticancer Ther 6 (2006) 1355-1359
-
(2006)
Expert Rev Anticancer Ther
, vol.6
, pp. 1355-1359
-
-
Monnier, A.1
-
50
-
-
14844358496
-
Clinical trial update: National Cancer Institute of Canada
-
Pritchard K., and Whelan T. Clinical trial update: National Cancer Institute of Canada. Breast Cancer Res 7 (2005) 48-51
-
(2005)
Breast Cancer Res
, vol.7
, pp. 48-51
-
-
Pritchard, K.1
Whelan, T.2
-
51
-
-
38949210774
-
Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS)
-
Abstract 583.
-
Melisko M., Lin A., and Rugo H. Adjuvant therapy for early stage breast cancer (EBC): Distant disease-free survival (DDFS) as a predictor of overall survival (OS). J Clin Oncol 25 18S (2007) 23S Abstract 583.
-
(2007)
J Clin Oncol
, vol.25
, Issue.18 S
-
-
Melisko, M.1
Lin, A.2
Rugo, H.3
|